Company news
Fulcrum Therapeutics, Inc. news in 2024
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Fulcrum Therapeutics to Participate in Upcoming December Conferences
November 25, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
November 12, 2024
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
November 11, 2024
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8: 00 a.m. ET
November 5, 2024
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
September 11, 2024
Fulcrum Therapeutics to Participate in Upcoming September Conferences
August 26, 2024
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
August 18, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
July 30, 2024
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8: 00 a.m. ET
July 23, 2024
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
June 11, 2024
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
June 5, 2024
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 12, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 12, 2024
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
May 7, 2024
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8: 00 a.m. ET
May 5, 2024
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
March 17, 2024
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
March 4, 2024
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 26, 2024
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8: 00 a.m. ET
February 19, 2024
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 5, 2024
Calls in 2024
- Fulcrum Therapeutics (NASDAQ:FULC) Q3 2024 Earnings Call
Nov 13, 2024
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q2 2024 Earnings Call
Jul 31, 2024
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q1 2024 Earnings Call
May 13, 2024
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q4 2023 Earnings Call
Feb 27, 2024
Transcript
Decks in 2024
- Technical Presentation (June 2024)
Technical · 16 slides · Jun 14, 2024